Medindia

X

Dyadic International to Announce Second Quarter 2010 Financial Results and Hold Conference Call on August 13, 2010

Thursday, August 5, 2010 Press Release J E 4
Advertisement

JUPITER, Fla., Aug. 5 /PRNewswire-FirstCall/ -- Dyadic International, Inc. (Pink Sheets: DYAI), a global biotechnology company, today announced that it will release financial results for the second quarter ended June 30, 2010 on Friday, August 13, 2010 before market open to be followed by a conference call at 11:00 a.m. Eastern Time.

(Logo: http://photos.prnewswire.com/prnh/20091214/DYADICLOGO )

(Logo: http://www.newscom.com/cgi-bin/prnh/20091214/DYADICLOGO )

The conference call may be accessed by dialing 888-724-9504 (domestic) or 913-312-0951 (international) five to ten minutes prior to start time and providing the passcode 4931751.

About Dyadic

Dyadic is a global biotechnology company that uses its patented and proprietary technologies for the discovery, development, manufacture and sale of enzyme products and solutions to address the needs of the bioenergy, biopharmaceutical and industrial enzyme markets. Please visit Dyadic's website at www.dyadic.com.

Cautionary Statement for Forward-Looking Statements

Certain statements contained in this press release are forward-looking statements. These forward-looking statements involve risks and uncertainties that could cause Dyadic's actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Except as required by law, Dyadic expressly disclaims any intent or obligation to update any forward-looking statements.

SOURCE Dyadic International, Inc.

Advertisement


Advertisement

You May Also Like

Advertisement
View All

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions
s
Published Study Demonstrated Once-Daily Vyvanse® (...
S
Merriman Curhan Ford Acted as Sell-Side Advisor to...